UN, Danaher, NHS & J&J: This Week's Top Healthcare Stories

UN Warns Healthcare Progress is at Risk as SDGs Stall

The United Nations (UN) has published its Sustainable Development Goals Report 2026, warning that strong healthcare gains achieved over the past decade risk stalling following declining international funding and external pressures.

According to the UN, only 36% of the 139 measurable targets are on track or making moderate progress with just four years to go until the 2030 deadline is reached. 

A further 49% are advancing too slowly and 15% have regressed since 2015.

Governments around the world have cut back on international funding due to sluggish economic growth, high debt burdens and political indifference. 

Most notably, the United States under the Donald Trump administration has cut USAID contracts, closed global health programmes and withdrawn from the World Health Organisation.

António Guterres, Secretary-General at the United Nations, says that "the direction we choose now will determine whether the progress of the past decade holds or unravels," as declining international funding threatens to reverse gains in global health, disease prevention and maternal care.

Julie Sawyer Montgomery Named Danaher President and CEO

Danaher will begin a new chapter in October 2026, when Julie Sawyer Montgomery takes the helm as CEO of the global life sciences and diagnostics company.

Rainer Blair, who has served as CEO since 2020, will retire from the role and continue supporting the transition as a senior advisor until 31 March 2027.

Commenting on Danaher’s leadership change, Steven Rales, Chairman of the Board of Directors at Danaher, says, "We are at a uniquely opportune moment for Danaher, with untapped potential to accelerate growth across the enterprise. Julie has the vision, experience, and proven track record to deliver on that potential.

“I am confident she will lead our Company into its next phase of growth and value creation with a demonstrated commitment to innovation, commercial excellence and operational rigour, all grounded in strategy.”

Danaher reaffirmed its Q3 and full-year 2026 guidance as part of the leadership change announcement. 

Tom Cavanaugh Appointed Head of J&J Innovative Medicine

From 1 September 2026, Johnson & Johnson's lucrative Innovative Medicine division will enter a new chapter under the leadership of Tom Cavanaugh, who succeeds Executive Vice President Jennifer Taubert following her retirement.

Jennifer will step down after 21 years with Johnson & Johnson, having served as EVP of Innovative Medicine since July 2018. During her tenure, she oversaw impressive growth, with annual revenues rising to US$60bn.

Tom joins the role from his current position as Company Group Chairman for Innovative Medicine's North American operations, bringing with him nearly three decades of biopharmaceutical experience. 

He will also become a member of Johnson & Johnson's Executive Committee when he assumes the position.

P&G’s Wellness Focus Grows Following US$3.8bn Thorne Deal

Global consumer goods giant Procter & Gamble (P&G) is expanding its Health Care portfolio following its US$3.8bn acquisition of Thorne, as the company looks to tap into rising consumer interest in self-care, preventive health and personalised wellness. 

P&G’s Health Care portfolio has evolved from a traditional consumer healthcare business centred on oral care and OTC medicines into a broader health and wellness platform. 

The global consumer health market exceeds an estimated US$375bn in retail sales, with P&G well-positioned to maintain its strong presence in the sector.

Household brands already within its Health Care portfolio include Vicks, Crest, Oral-B, Metamucil, Pepto-Bismol, Fixodent, and Neurobion, alongside supplement brands Align Probiotic and New Chapter.

Survey: 9 in 10 NHS Staff Use AI Amid Rising Admin Burden

A survey of 1,000 NHS healthcare professionals commissioned by Heidi has found that AI is a central part of their day-to-day work as clinicians seek relief from rising administrative burden.

Heidi is an AI-powered ambient voice technology (AVT) developer that agreed a deal to roll out transcription technology across NHS Midlands in July 2026 – the first region to procure an AI-powered AVT provider at scale. 

The results show widespread AI adoption by healthcare professionals working in the NHS, with 90% of respondents using AI in their clinical work and 65% largely navigating the technology ahead of formal workplace guidance. 

AI demonstrably already exists within clinician workflows, offering a clear pathway to build on the progress healthcare professionals have made by expanding access to, and use of, clinician-led AI tools with robust governance, according to Dr Hannah Allen, Chief Medical Officer and GP at Heidi.

"These findings reflect what we hear every day from patients and clinicians. Patients are ready for this, and healthcare professionals have already made AI part of how they manage a workload that has grown well beyond what most would call sustainable,” Hannah says.